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Abstract 
Many common diseases have a complex genetic basis in which large numbers of genetic variations combine with 
environmental and lifestyle factors to determine risk. However, quantifying such polygenic effects and their 
relationship to disease risk has been challenging. In order to address these difficulties we developed a global 
measure of the information content of an individual’s genome relative to a reference population, which may be 
used to assess differences in global genome structure between cases and appropriate controls. Informally this 
measure, which we call relative genome information (RGI), quantifies the relative “disorder” of an individual’s 
genome. In order to test its ability to predict disease risk we used RGI to compare single nucleotide polymorphism 
genotypes from two independent samples of women with early-onset breast cancer with three independent sets of 
controls. We found that RGI was significantly elevated in both sets of breast cancer cases in comparison with all 
three sets of controls, with disease risk rising sharply with RGI (odds ratio greater than 12 for the highest 
percentile RGI). Furthermore, we found that these differences are not due to associations with common variants at 
a small number of disease-associated loci, but rather are due to the combined associations of thousands of markers 
distributed throughout the genome. Our results indicate that the information content of an individual’s genome 
may be used to measure the risk of a complex disease, and suggest that early-onset breast cancer has a strongly 
polygenic basis.  !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
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Author Summary  
Recent years have seen significant advances in our understanding of the genetic basis of breast cancer, and a 
number of markers, such as the BRCA1 and BRCA2 genes, are well-known to be associated with increased 
disease risk. However, mutations in these genes do not fully account for the genetic basis of breast cancer, and it 
has proven difficult to identify other powerful markers with high confidence. Accumulating evidence suggests 
that breast cancer has a multifactorial basis, in which numerous genetic variations combine with environmental 
and lifestyle factors to determine risk. Here we introduce a simple measure of the information content of an 
individual’s genome and use this measure to show that breast cancer susceptibility is associated with increased 
genome-wide “disorder”, involving subtle alterations in thousands of locations throughout the genome. Our 
results indicate that information theoretic methods may be used to measure the risk of a complex disease, and 
suggest that early-onset breast cancer has a strongly polygenic basis. 
Introduction 
Accumulating evidence suggests that many common diseases have a polygenic basis, in which large numbers of 
genetic variations combine with environmental and lifestyle factors to determine risk (Khoury M.J. 2013). While 
genome-wide association studies (GWAS), and more recently exome and whole genome sequencing projects, 
have found hundreds of genetic variants that are associated with disease, the ability to predict susceptibility from 
these associations is generally low because the contribution of individual variants to risk is often very modest. In 
the case of breast cancer, the published GWAS have identified markers (single nucleotide polymorphisms, or 
SNPs) in more than 70 independent regions (loci), the majority with odd ratios less than 1.1 (Bogdanova et al. 
2013). Collectively these loci explain, in the statistical but not causative sense, approximately 15% of the familial 
relative risk which, when combined with the approximately 21% attributed to moderate- to high-penetrance 
variants (typically very rare mutations) in a dozen or so susceptibility genes, leaves almost two thirds of the 
familial basis of the disease unaccounted for (Antoniou and Easton 2006; Bogdanova et al. 2013). It is likely that 
additional genes that explain a proportion of this missing heritability will be found using both whole 
exome/genome and candidate gene sequencing of familial and young-onset cases, where the genetic component of 
risk is likely to be greatest (Akbari et al. 2014; Hopper and Carlin 1992; Manolio et al. 2009; Park et al. 2012; 
Ruark et al. 2013). However, despite such advances, our current understanding of the genetic basis of breast 
cancer is far from complete. 
While most studies to date have focussed on individual genes or gene mutations and their contribution to disease, 
there has been limited effort to quantify the cumulative effect of variation across the whole genome on disease 
risk. This is partly due to the historical lack of sufficient data to appropriately quantify normal genomic variation 
within control populations, and the absence of the statistical techniques needed to analyse such large-scale 
variation. However, recent years have seen concerted effort to collect and collate the large numbers of genomes 
(for example the UK Department of Health’s 100K initiative http://www.genomicsengland.co.uk) and there is 
now a need to develop the accompanying methodological tools to assess genomic variation.  
In order to begin to address this issue we describe here a measure of the extent to which a set of case genomes 
differ from a set of control genomes in their global structure. Our method uses ideas from information theory to 
provide a measure of the information content of an individual’s genome with reference to a control population 
(detailed in Methods below). The essential procedure involves using the reference population to estimate a 
probability measure on the space of all genomes, and then using the estimated measure to assess how unusual an 
individual’s genome is with respect to the reference population, as quantified by its self-information (also known 
in information theory as “surprisal”) (Cover and Thomas 1991). Formally, the resulting measure, which we refer 
to as the relative genome information (RGI), is the amount of information, measured in bits, required to specify 
the observed genome with respect to the unique encoding that minimises the expected number of bits required to 
specify the genome of an individual drawn at random from the reference population. Informally, the RGI 
measures how unusual a genome is with respect to the reference population or, since we construct an information-
theoretic measure closely related to the Shannon entropy, how “disordered” it is. Thus, someone with a higher 
RGI has a more unusual genome, either having less common alleles more often than expected, or having some 
particularly rare alleles. By contrast a lower RGI corresponds to having more common alleles more often, and 
therefore a less surprising genome.  
We hypothesised that global measures of genome variation, such as RGI, might quantify the polygenic basis of 
complex diseases more completely than GWAS analyses that seek to find statistically significant associations of 
particular markers with disease. In order to test this hypothesis we compared the RGI of two independent samples 
of women with early-onset breast cancer genotyped for SNPs relative to three independent samples of unaffected 
controls (Dite et al. 2003; Eccles et al. 2007; Goodwin et al. 2012; McCredie et al. 1998; Phillips et al. 2005). 
Methods 
Data Normalization 
SNP genotypes obtained from blood samples from the following three independent studies were considered: (i) 
The Prospective study of Outcomes in Sporadic versus Hereditary breast cancer (POSH) cohort (Eccles et al. 
2007). The POSH cohort consists of approximately 3,000 women aged 40 years or younger at breast cancer 
diagnosis from which 574 cases were genotyped on the Illumina 660-Quad SNP array. Genotyping was conducted 
in two batches at separate locations: the Mayo Clinic, Rochester, Minnesota, USA (274 samples) and the Genome 
Institute of Singapore, National University of Singapore (300 samples). Only 536 samples that passed quality 
control filters were considered in this study (Rafiq et al. 2013). (ii) The Wellcome Trust Case Control Consortium 
(WTCCC, http://www.wtccc.org.uk/). The WTCCC consists of approximately 5,000 disease-free controls 
including individuals from the 1958 British Birth Cohort and from the UK National Blood Service (NBS) 
Collection. Genotyping was conducted using the Illumina 1.2M chip. (iii) The Australian Breast Cancer Family 
Study (ABCFS) (Dite et al. 2003; McCredie et al. 1998). Cases were a subset of 204 of women aged 40 years or 
younger at breast cancer diagnosis from the ABCFS; controls were 287 unaffected women aged 40 years and 
older from the Australian Mammographic Density Twins and Sisters Study (Odefrey et al. 2010). Genotyping was 
conducted at the Australian Genome Research Facility using the Illumina 610-Quad SNP array.   
Only autosomes were considered and SNPs were excluded from each dataset if they failed any of the following 
quality control filters: minor allele frequencies < 1%; genotyping call rate < 99%; significant deviation from 
Hardy-Weinberg equilibrium (! < 0.0001). All quality control filters were implemented using the software 
package PLINK (Purcell et al. 2007). In total approximately 475,000 SNPs were genotyped in all five datasets. 
When comparing datasets and computing RGI only these shared SNPs were considered. 
Individuals with evidence of ethnic admixture were excluded by performing multi-dimensional scaling (MDS) 
analysis using linkage disequilibrium (LD) based pruning (!! > !0.5) of genotypes in PLINK. This procedure 
generates a reduced set of approximately independent SNPs. In total there were approximately 133,000 LD-
pruned SNPs common to all samples. HapMap data for the African, Asian and Caucasian populations (Gibbs et 
al. 2003) were also used to provide reference population genotypes against which the genotype data of our cases 
and controls were compared (Fig. 1a). We identified eight POSH and ten ABCFS samples that showed evidence 
of mixed ethnicity, and these were excluded from further analysis. Conclusions did not differ without removal of 
these samples. 
 
Quantifying Relative Genome Information 
Let ! denote a set of locations in the genome (loci), and let ! = !,!,!,!  be the alphabet of possible alleles at 
each locus ! ∈ !. Let Π! !!, !  denote the likelihood of finding the unordered allele pair !, ! ∈ !×! at locus ! ∈ ! in the reference population and let Π be the product measure of Π! over all ! ∈ !. Thus, Λ!! denotes the 
space of all possible genomes, and Π represents the probability measure on Λ!!. Now let ! ∈ Λ!! be a genome 
with allele pair !! ∈ !×! at locus ! ∈ !. We define the relative local information (RLI) !! !! = −log!Π! !!!  at 
each locus ! ∈ ! in the genome ! and the relative genome information (RGI) ! ! = !! !!!!∈!  for each genome ! of interest. For the purposes of comparison it is also convenient to normalize the RGI by !, the number of loci 
genotyped, to give the expected information per locus (EIL), !! !! = !! !! !!!!∈! . When comparing sequences 
of the same length the EIL and RGI are equivalent up to a normalizing factor. However, by normalizing by the 
number of loci sampled, the EIL allows comparison of relative information content of sequences of different 
lengths (for instance, comparison of relative information content of different chromosomes). The RLI is the 
natural information-theoretic measure of the “surprisal” of observing allele pair !! ∈ !×! at locus ! ∈ ! given the 
probability measure Π! (Cover and Thomas 1991). Similarly, the RGI is the natural information-theoretic measure 
of the surprisal of observing the genome !, given the probability measure Π.  
In practice Π is not known a priori and must be estimated from an appropriate reference sample of similar ethnic 
background to that of the cases. Here, we estimated Π using the WTCCC 1958 birth cohort since it was the largest 
reference sample. In all calculations, Π! was estimated for each locus!! ∈ ! using all available genotypes in the 
reference population at that locus. Once Π had been approximated, the RGI was calculated for each genome in 
each of the remaining four (test) samples (POSH cases, ABCFS cases, ABCFS controls, NBS controls). The two 
additional independent sets of controls (ABCFS and NBS) were included in order to assess the robustness of the 
approximation of the background probability measure Π from the 1958 cohort alone. For each of the four test 
samples, missing genotype data at each locus ! ∈ ! were assigned the expected value of Π! (i.e. the Shannon 
entropy − Π! !!!!!! log!Π! !!!  of Π!). This method of imputation minimizes the influence of missing data on 
the calculation of RGI. We also conducted all calculations using only those loci for which there were no missing 
readings in any of the datasets, and results obtained with and without imputation did not differ qualitatively. A 
brief worked example illustrating how Π was estimated, and the RLI and RGI were calculated, is given in the 
Supplementary Materials. Estimation of RGI for ! case genomes takes !(!(! + !)) computational time, where ! is the number of loci and ! is the number of genomes in the control population, and can be conducted on a 
desktop PC for moderate sample sizes (thousands of samples and hundreds of thousands of genotyped loci).  
 
Statistical analysis 
All analysis was conducted in R and Matlab using custom written scripts. The association between EIL and 
disease odds was estimated using a logistic generalized additive model (Hastie et al. 2009). Tests for significant 
differences between groups were assessed using Wilcoxon rank-sum tests. All p-values were false-discovery rate 
(FDR) adjusted using the Benjamini-Hochberg procedure (Benjamini and Hochberg 1995).  
 
Results 
We did not observe any difference in expected information per locus (RGI normalized by the number of loci 
genotyped, EIL) between the three different control sets (1958 controls, NBS controls, ABCFS controls) 
indicating that the background measure Π was reliably estimated; similarly, no difference in EIL between the 
POSH and ABCFS cases was observed (Fig. 1b-c). However, EIL was significantly higher in both the POSH and 
ABCFS cases than the three sets of reference controls (FDR adjusted ! < 0.01, two-sided Wilcoxon rank-sum 
test)  (Fig. 1b-c). Since significant differences within case and control sets were not observed, we amalgamated 
samples to form one case set (consisting of the ABCFS and POSH cases) and one control set (consisting of the 
ABCFS, NBS and 1958 controls) for further analysis. Comparison of the distribution of RGI in amalgamated case 
set and amalgamated control set revealed significant differences in distribution structure (! = 4.3×10!!", two-
sample Kolmogorov-Smirnov test) with the case distribution having a substantially heavier tail than the control 
distribution, indicating a greater proportion of samples with higher EIL (Fig. 1d). To investigate further we 
conducted regression using a logistic generalized additive model (Hastie et al. 2009) in order to estimate the 
relationship between disease odds ratio and EIL (Fig. 1e). Consistent with the heavy-tailed nature of the case 
distribution we observed a strong positive association between odds ratio and EIL. In particular, the odds ratio 
increased sharply for EIL above 1.75, with the highest percentile EIL (above 1.183) having an odds ratio greater 
than 12 (! < 1×10!!", Fisher’s exact test). These results indicate that EIL is significantly elevated in breast 
cancer cases, with the highest percentiles EIL conferring a substantially increased risk.  
In order to investigate the genetic basis for these observations we sought to assess whether the differences 
observed were associated with particular genomic loci or SNP annotations. We began by estimating the number of 
loci required to account for observed differences at each percentile using random resampling with replacement 
(1×10! times) from the case genomes until the required difference was achieved. Differences in median EIL 
between cases and controls were found to be due to contributions from an estimated 327 distinct loci (95% 
confidence intervals [306, 349]) (Fig. 1f). The expected number of loci required to account for differences 
between cases and controls sharply increased with percentile, with differences in the 99th percentile (which 
conferred the greatest disease risk) requiring an estimated 4954 loci (95% confidence intervals [4921, 5000])  
(Fig. 1f). These results indicate that observed differences in EIL are not due to high-penetrance variations at a 
small number of disease-associated loci, but rather are due to widespread variation at thousands of genomic loci.  
In order to investigate this further we assessed the EIL on individual chromosomes. We found that EIL was 
consistently elevated in the cases by comparison with the controls on 19 of 22 chromosomes (Fig. 2a), and 
significantly so on 12 of 22 chromosomes (FDR adjusted ! < 0.05 , one-sided Wilcoxon rank-sum test), 
indicating that differences in EIL are distributed throughout the genome. We also observed notable variations in 
EIL by SNP annotation, with the lowest EIL (and therefore the least variation within the samples) occurring in the 
5’/3’ untranslated and exonic regions, and the highest EIL (and therefore the greatest variation within the 
samples) occurring in the intergenic regions. This is consistent with previous assessment of relative mutation rates 
and suggests that 5’/3’ UTRs and exonic regions are subject to stronger negative selection than intergenic regions, 
in accordance with their phenotypic importance (Khurana et al. 2013; Ward and Kellis 2012a, 2012b). In all 
annotation categories, we again observed a significant increase in EIL in the cases (FDR adjusted ! < 0.05, one 
sided Wilcoxon rank-sum test). These results indicate that observed differences in EIL are not localized to distinct 
regions of the genome (either chromosomes or SNP annotations) but rather are due to widespread variation 
distributed throughout the genome. 
In order to assess whether increased genomic disorder affects disease prognosis we also looked for associations 
between EIL and Nottingham Prognostic Index (NPI) (Galea et al. 1992) and age at diagnosis within the POSH 
cases (corresponding information for the ABCFS cases was not available). However, we found no significant 
associations (Fig. 2d-e) suggesting that, within the power of this study, EIL is not a predictor of outcome or age of 
onset although, due to the small number of samples with complete information, this possibility cannot be 
excluded. 
Taken together, our results indicate that genome-wide disorder is positively associated with breast cancer risk.  
Prior to analysis all genotyping data were subjected to stringent quality assurance and we observed no association 
between sex, sequencing platform, time/place of sequencing and EIL, indicating that poor data quality or variation 
in genotype due to ethnicity or sex are unlikely to explain our results (Fig. 1b-c, Fig. 2f). Rather, changes in EIL 
appear to quantify biologically meaningful differences in large-scale genome structure between breast cancer 
cases and controls.  
 
Discussion 
Many of the currently known moderate- and high-risk cancer susceptibility genes code for proteins involved in 
DNA repair, and DNA damage signatures found in tumour tissue may reflect a core component of the underlying 
aetiology of cancer (Nik-Zainal et al. 2012a; Nik-Zainal et al. 2012b; Stephens et al. 2012). Thus, DNA repair 
deficiencies may have a role in elevating the EIL in cancer cases. Although signs of tumour-associated DNA 
repair deficiencies are not typically found in normal blood derived DNA samples, two recent reports indicate that 
inherited DNA repair deficiency can be detected in DNA extracted from peripheral blood lymphocytes (Ingham et 
al. 2013; Ruark et al. 2013). It is possible that rapid cellular replication subsequent to chemotherapy-induced 
myelosupression could amplify such signals. However, we found no evidence of association between EIL and 
chemotherapy status (Fig. 2c), suggesting that this is not the case. An alternative possibility is that variation in 
genome-wide disorder (and therefore EIL) arises due to polymorphisms in genes associated with the DNA 
damage repair pathways that safeguard germline integrity during oogenesis (Kerr et al. 2012; Levine et al. 2011; 
Suh et al. 2006). By regulating the fidelity with which genomic information is transmitted between generations 
such polymorphisms could generate variations in the rate of production of de novo mutations in successive 
generations that affect susceptibility to disease in later life. While we have not tested this hypothesis directly, our 
results are consistent with this perspective.  In future familial studies it would be interesting to assess whether 
parental mutations in the p53/p63/p73 pathways (which have a central role in protection of the maternal and 
paternal genomes) (Levine et al. 2011) are associated with increased genomic disorder in their offspring.   
Taken together our analysis indicates that early-onset breast cancer has a strongly polygenic basis, involving 
variation at thousands of markers distributed throughout the genome. Thus, along with assessment of known risk-
associated variants, the information content of an individual’s genome is a useful predictor of disease 
susceptibility. Further analysis of the relationship between global genome structure and disease risk may reveal a 
similarly polygenic basis for a variety of other complex diseases.  !
Figure legends 
Figure 1. (a) Multidimensional scaling plot of all samples and HapMap2 populations genotyped for ~133,000 
SNPs. (b) Expected information per locus (EIL) for each of the different datasets. Median ± 95% confidence 
intervals are shown. (c) Matrix of FDR adjusted p-values for comparisons of medians (two-sided Wilcoxon rank-
sum test). (d) Q-Q plot of EIL in cases versus controls. p-value from a two-sample Kolmogorov-Smirnov test is 
shown. (e) Estimated odds ratio as a function of EIL. (f) The number of loci that account for the differences in 
EIL observed between cases and controls by percentile. 95% confidence intervals are within the markers, so are 
not shown. 
 
Figure 2. (a) Expected information per locus (EIL) by chromosome. Median ± 95% confidence intervals are 
shown. Stars indicate significant changes at FDR adjusted ! < 0.05 by one-sided Wilcoxon rank-sum test. (b) 
Relationship between EIL and chemotherapy status in the POSH cohort. (c) Relationship between EIL and 
Nottingham Prognostic Index (NPI) in the POSH cohort. (d) Relationship between EIL and age at diagnosis in the 
POSH cohort. In panels (b-d) p-values for Spearman tests for association are shown. (f) EIL in males and females 
in the controls. Median ± 95% confidence intervals are shown. !
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Supplementary Materials 
A worked example 
Consider sampling 5 individuals from an unknown background population. In this illustrative example there 
are 2 letters in the alphabet ! = !,!  and at a particular locus the following alleles are observed:  
 
 Individual 1 Individual 2 Individual 3 Individual 4 Individual 5 
Locus 1 AA AA AA BB BA 
 
To estimate the true probability of finding each allele pair in the background population we count the 
frequencies of the alleles A and B to obtain: 
!(!) = 710 , !(!) = 310. 
We may then estimate the Hardy-Weinberg proportions: 
Π! !! ≈ ! ! ×!(!) = 710 !, 
Π!(!!) ≈ !(!)×!(!) = 310 !, 
Π! !" = Π!(!") ≈ 2×!(!)×!(!) = 2× 710 × 310 . 
The RLI for each pair is found by taking the negative logarithm of these probabilities: −log!(Π!(!!)) = 1.0291, −log!(Π!(!!)) = 3.4739, −log!(Π!(!")) = 1.2515, 
where logarithms are taken to base 2 so that information is measured in bits. Since the pair BB is rare in the 
population it imparts more information whenever it is observed; by contrast since the pair AA is common, it 
imparts less information whenever it is observed.  
Suppose now that a second locus is also sequenced and the following alleles are observed: 
 Individual 1 Individual 2 Individual 3 Individual 4 Individual 5 
Locus 2 AA BA BA BB AA 
 
A similar calculation yields the RLI of the second locus and the RGI for each individual (here, the ‘genome’ 
has just 2 loci):  
 
 Individual 1 Individual 2 Individual 3 Individual 4 Individual 5 
RLI 1 1.0291 1.0291 1.0291 3.4739 1.2515 
RLI 2 1.4739 1.0589 1.0589 2.6439 1.4739 
RGI 2.5030 2.0880 2.0880 6.1178 2.7254 
 
In this case, individual 4 has the least common alleles at both loci, and correspondingly has the largest RGI. 
Individuals 2 and 3 have the most common alleles are therefore the lowest RGI. In this calculation the five 
individuals form the control population from which the probability measure Π on Λ!! is approximated. Once 
this measure has been approximated, it may be used to assess the RGI of unseen case genomes. For example, 
a case individual with the genome [AA, BB] has RGI = 1.0291 + 2.6439 = 3.673. !
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